Sign up United Kingdom
OptiBiotix Health plc (LON:OPTI)

OptiBiotix Health plc (LON:OPTI)

Share Price
73.00 p
-1.5 (-2.01 %)
Market Cap
£61.00 m
Proactive Investors - Run By Investors For Investors

OptiBiotix Health plc RNS Release

Directorate Changes

RNS Number : 1283B
OptiBiotix Health PLC
08 January 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")


Directorate changes


OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announces that further to the announcement dated 5 December 2017, Richard Colin Neil Davidson CBE has been appointed as Non-Executive Chairman to the Company. Simultaneous with Mr Davidson's appointment, Adam Reynolds, as previously disclosed, has stepped down as a director of the Company.


Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Richard Colin Neil Davidson CBE (aged 66):


Current Appointments

Appointments in the last 5 years

Bridge4 Health Limited

Competition Law Process Management Limited

Bridge4 Rehabilitation Limited

Eminate Limited

Cricketarchive Limited

Maplewell Limited

Eclipse Film Partners No.38 LLP

Persimmon Plc

Foodzeen Limited

Produce Investments Plc

T S Bloor & Sons Limited

Television Nottingham Limited Limited


The Cricketer Publishing Limited


Thixate Limited


United Church Schools Foundation Limited


United Learning Trust


WM Morrison Supermarkets Plc


Wireframe IO Limited



There is no information regarding Mr Davidson required to be disclosed under the AIM Rules.


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information, please contact:


OptiBiotix Health plc

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP

Tel: 020 7213 0880

Liam Murray / Jo Turner




finnCap Broker

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)


Tony Quirke (Corporate Broking)




Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Anna Dunphy

Mob: 07876 741 001



About OptiBiotix -

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 


The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 


OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.


This information is provided by RNS
The company news service from the London Stock Exchange

OptiBiotix Health plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use